Pharmacologic approaches to reversing multidrug resistance

Area of Science:

• Pharmacology and Oncology
• Cancer Biology and Drug Resistance

Background:

• Multidrug resistance (MDR) mediated by P-glycoprotein (P-gp) is a significant challenge in cancer chemotherapy.
• P-gp expression in tumors correlates with poor prognosis and treatment failure.
• Existing MDR modulation strategies face limitations in achieving effective drug levels and addressing multifactorial resistance mechanisms.

Purpose of the Study:

• To evaluate the potential of novel, potent P-gp inhibitors, specifically PSC 833, to overcome MDR in cancer.
• To investigate the challenges and potential solutions for clinical application of MDR modulators.
• To assess the safety and efficacy of PSC 833 in combination with cytotoxic agents.

Main Methods:

• Review of rationale for P-gp inhibition in MDR.
• Analysis of limitations in previous clinical trials of MDR modulators.
• Examination of drug interaction profiles of PSC 833 with cytotoxic agents.
• Evaluation of preclinical data from knockout mice lacking P-gp.
• Assessment of early Phase I and II clinical trial data for PSC 833.

Main Results:

• P-gp expression is a validated target for MDR modulation in preclinical cancer models.
• PSC 833 demonstrates potent P-gp inhibition, potentially overcoming previous limitations.
• Drug interactions with PSC 833 are predictable and manageable through dose adjustments.
• Early clinical data show substantial P-gp inhibition at tolerable doses of PSC 833 and cytotoxins.
• P-gp plays a significant role in drug disposition, as supported by knockout mouse studies.

Conclusions:

• PSC 833 represents a promising new agent for MDR modulation in cancer therapy.
• Further research is needed to understand and overcome alternative resistance mechanisms.
• Phase III clinical trials are underway to determine the ultimate therapeutic benefit of PSC 833 in AML and multiple myeloma.